Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
Guangzhou Baiyunshan Pharmaceutical Co., Ltd. is one of China’s largest TCM (Traditional Chinese Medicine) enterprises. It is a leading manufacturer of pharmaceuticals and Chinese medicine as well as active pharmaceutical ingredients. The company was founded in 1934, and is headquartered in Guangzhou, China. Being located in the Pearl River Delta of Guangdong Province in southern China, it has access to the relatively low-cost production in the region and thus enjoys cost advantages in its products compared to other competitors.
Guangzhou Baiyunshan Pharmaceutical Co., Ltd.’s products are not only sold in China but also exported to countries such as the US, European Union, and Japan. The company is dedicated to research and development of new products and technology. Its R&D focus is on new drug formulation, upstream and downstream technology, and small molecule synthesis. The company is also actively working to develop innovative formulations for specific TCM products and traditional Chinese medicinal plants.
The company’s main businesses include traditional medicinal decoctions, modern Chinese patent medicines, TCM raw materials, Chinese herb extracts and Chinese herbal products. Its product portfolio consists of dozens of compounds that are made up of traditional Chinese patents and decoctions. The company also works with hospitals and institutes to conduct research and development of new products, as well as production.
In terms of growth, Guangzhou Baiyunshan Pharmaceutical Co., Ltd.’s features a solid track record over the years. In 2018, the company’s total revenue increased by 8.7% year-on-year, of which total sales revenue increased by 10.4% year-on-year. The company’s net profit reached 905 million yuan, indicating a growth of 39%.
With globalization, the company has also adapted with the times, proactively participating in international standardization and establishing international relationships. It is the first Chinese TCM enterprise to acquire a US Food and Drug Administration (FDA) drug in 2009. At present, the company has built up a strong international presence with its products being sold in over 80 countries and regions.
Looking ahead, Guangzhou Baiyunshan Pharmaceutical Co., Ltd. is well-positioned to become a major player in the pharmaceutical industry with its strong R&D capabilities and established market presence. The company has grown rapidly in recent years, and as long as it can continue to develop new products and expand into new markets, this growth should continue.
